Tempus AI Future Growth
Future criteria checks 3/6
Tempus AI is forecast to grow earnings and revenue by 72.1% and 21.7% per annum respectively. EPS is expected to grow by 79.8% per annum. Return on equity is forecast to be 29.7% in 3 years.
Key information
72.1%
Earnings growth rate
79.83%
EPS growth rate
Life Sciences earnings growth | 16.6% |
Revenue growth rate | 21.7% |
Future return on equity | 29.67% |
Analyst coverage | Good |
Last updated | 19 May 2025 |
Recent future growth updates
The Tempus AI, Inc. (NASDAQ:TEM) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 09Earnings Update: Here's Why Analysts Just Lifted Their Tempus AI, Inc. (NASDAQ:TEM) Price Target To US$64.11
Feb 27Recent updates
The Tempus AI, Inc. (NASDAQ:TEM) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 09Tempus: The AI Engine Powering Healthcare
Apr 20Is Tempus AI (NASDAQ:TEM) A Risky Investment?
Mar 25Tempus AI's Valuation Bakes In Strong Growth - A Hold For Now
Mar 25Tempus AI: The Investment Opportunity Of A Decade, Strong Buy
Mar 18Earnings Update: Here's Why Analysts Just Lifted Their Tempus AI, Inc. (NASDAQ:TEM) Price Target To US$64.11
Feb 27Tempus AI Earnings: A Promising Business, But There Are Risks
Feb 25Tempus AI Is A Buy On Dips In The AI-Driven Healthcare Sector
Feb 18Why Investors Shouldn't Be Surprised By Tempus AI, Inc.'s (NASDAQ:TEM) 82% Share Price Surge
Feb 11Tempus AI: In Vogue, But Better To Wait For Some Retracement
Feb 05Tempus AI: Don't Be Blindly Optimistic On Anything AI
Jan 28Tempus AI: Why I'm Avoiding This Stock In 2025
Jan 21The Price Is Right For Tempus AI, Inc (NASDAQ:TEM) Even After Diving 26%
Dec 18Tempus AI: Recent Weakness Presents Gift Ahead Of The Holidays
Dec 18Tempus AI: Why I'm Buying This AI Stock
Dec 08Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven Innovation
Nov 12Tempus: Attempting To Lead The AI Revolution In Healthcare
Oct 29Tempus AI: Deploying AI In Precision Medicine; Initiate With 'Buy'
Aug 21Tempus AI: Healthcare AI Play Faces Some Challenges From The Start
Jun 14Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2027 | 1,933 | -104 | 73 | 140 | 6 |
12/31/2026 | 1,556 | -184 | 7 | 73 | 12 |
12/31/2025 | 1,247 | -298 | 208 | -64 | 12 |
3/31/2025 | 803 | -721 | -213 | -193 | N/A |
12/31/2024 | 693 | -746 | -211 | -189 | N/A |
9/30/2024 | 640 | -801 | -207 | -190 | N/A |
6/30/2024 | 596 | -790 | -325 | -292 | N/A |
3/31/2024 | 562 | -293 | -284 | -249 | N/A |
12/31/2023 | 532 | -266 | -249 | -214 | N/A |
9/30/2023 | 485 | -276 | -266 | -233 | N/A |
12/31/2022 | 321 | -334 | -187 | -168 | N/A |
9/30/2022 | 293 | -325 | -192 | -173 | N/A |
12/31/2021 | 258 | -298 | -224 | -212 | N/A |
9/30/2021 | 285 | -296 | -205 | -193 | N/A |
6/30/2021 | 284 | -286 | -199 | -188 | N/A |
3/31/2021 | 236 | -270 | -209 | -198 | N/A |
12/31/2020 | 188 | -254 | -220 | -207 | N/A |
12/31/2019 | 62 | -148 | -134 | -117 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TEM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TEM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TEM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TEM's revenue (21.7% per year) is forecast to grow faster than the US market (8.5% per year).
High Growth Revenue: TEM's revenue (21.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TEM's Return on Equity is forecast to be high in 3 years time (29.7%)
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/05/20 10:21 |
End of Day Share Price | 2025/05/20 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tempus AI, Inc. is covered by 13 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Michael Ryskin | BofA Global Research |
Mark Massaro | BTIG |
Subhalaxmi Nambi | Guggenheim Securities, LLC |